We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Celadon Pharmaceuticals Plc | LSE:CEL | London | Ordinary Share | GB00BDQYGP38 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1.50 | 2.52% | 61.00 | 57.00 | 65.00 | 61.00 | 59.50 | 59.50 | 3,683 | 14:00:11 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Investment Advice | 149k | -7.14M | -0.1082 | -5.50 | 39.26M |
From Jul 2019 to Jul 2024
TIDMCEL
RNS Number : 6145N
Caparo Energy Ltd
05 September 2011
Caparo Energy Limited
("Caparo Energy" or the "Company")
Result of EGM
Caparo Energy announces that at the Extraordinary General Meeting ("EGM") of the Company held earlier today, all Resolutions, as set out in the notice of EGM sent to shareholders on 10 August 2011, were duly passed.
Change of name of the Company
As the Company announced on 10 August 2011, and in light of the Company's ongoing transformative growth, its identity has evolved and the Board now considers it appropriate to change the name of the Company to Mytrah Energy Limited. Following the approval of the resolution today this change is expected to become effective on Wednesday 7(th) September and trading of the shares under this name are expected to commence at 8.00am under AIM ticker MYT.
Authority to issue shares and to disapply pre-emption rights
In addition, following the passing of the Resolutions, the Company is now authorised to issue Ordinary Shares on a non pre-emptive basis by dis-applying the pre-emption rights under the Company's Articles of Incorporation. The Board believes that the ability to issue new Ordinary Shares on a non pre-emptive basis is in the best interests of the Company as this affords considerable flexibility and a significant reduction in time and costs in effecting fundraisings.
Following the passing of the Resolutions the Board now intends to investigate the most appropriate method of implementing the Company's strategy, to the benefit of the Company and Shareholders as a whole.
Further information on the Company can be found at www.caparoenergy.com.
- Ends -
For further information please contact:
Caparo Energy Limited Ravi Kailas, Chairman and Chief Executive Officer +91 40 4396 0000 Strand Hanson Limited Angela Peace / Paul Cocker / James Harris +44 (0) 20 7409 3494 Mirabaud Securities LLP Peter Krens / Rory Scott +44 (0) 20 7878 3360 Pelham Bell Pottinger Charles Vivian / Philippe Polman +44 (0) 20 7861 3232
This information is provided by RNS
The company news service from the London Stock Exchange
END
REGLAMLTMBAMMIB
1 Year Celadon Pharmaceuticals Chart |
1 Month Celadon Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
